Market Overview - The Shanghai Composite Index closed at 3393.26 points, above the six-month moving average, with a change of 0.23% [1] - The total trading volume of A-shares reached 838.618 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 184 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 11.69% deviation, closing price 14.38 yuan, with a daily increase of 20.03% and turnover rate of 15.50% [1] - Haochen Medical: 8.62% deviation, closing price 3.12 yuan, with a daily increase of 9.86% and turnover rate of 6.44% [1] - Jinyinhai: 7.58% deviation, closing price 21.00 yuan, with a daily increase of 9.66% and turnover rate of 6.43% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Guangyun Technology: 7.45% deviation, closing price 14.13 yuan, with a daily increase of 9.20% and turnover rate of 4.78% [1] - Yaowang Technology: 5.93% deviation, closing price 7.12 yuan, with a daily increase of 7.88% and turnover rate of 13.64% [1] - Nuotai Biotech: 5.91% deviation, closing price 55.37 yuan, with a daily increase of 10.36% and turnover rate of 5.58% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month moving average include: - Guangdong Hongtu: just above the six-month line [1] - Xinhe Shares: just above the six-month line [1] - Songjing Shares: just above the six-month line [1]

Policy Developments - The National Health Commission is promoting the implementation of the "Blood Fee Waiver, No Need to Run Once" policy, aiming for full compliance by the end of 2025 across all blood stations and medical institutions in the country [1] Drug and Device Approvals - LuKang Pharmaceutical announced that its subsidiary has received approval for the consistency evaluation of Cimetidine Injection, which is used to treat symptoms caused by excessive stomach acid [2] - Baiyunshan reported that its subsidiary has received a drug registration certificate for Tadalafil Tablets, which are primarily used to treat erectile dysfunction [3] - Fuyuan Pharmaceutical announced that its subsidiary has received a drug registration certificate for Bromhexine Hydrochloride Oral Solution, suitable for treating respiratory diseases related to mucus secretion or clearance [4] Capital Market Activities - Tianxing Medical's IPO on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor [5] - NuoTai Bio and NuoWeiZan signed a strategic cooperation agreement for a synthetic biology project, planning to establish a joint biopharmaceutical company [6] Industry Events - A medical team in the UK is experimenting with processing healthy human feces into freeze-dried powder to help patients infected with superbugs, showing promising results [8] - Huazhong University of Science and Technology has opened the first brain-computer interface outpatient clinic in Central China, aiming to provide assessments and consultations for patients [9] - Kelong Pharmaceutical responded to accusations regarding its Ergotamine Capsules, clarifying that the product is classified as a dietary supplement rather than a drug [10] - Green Valley Pharmaceutical has halted production of the controversial drug Mannitol Sodium Capsules due to expired registration and ongoing scrutiny of its clinical trials [11] - Weili Zhibo Biotechnology has received approval from the China Securities Regulatory Commission for its IPO and the full circulation of its unlisted shares [12][14]

Core Points - Nanjing Novogene Bioinformatics Technology Co., Ltd. has been awarded the 25th China Patent Excellence Award for its invention patent "A Taq DNA Polymerase Mutant Mut4 and Its Application" [1][2] - The award is a recognition of the company's technological innovation capabilities and intellectual property efforts, which will help enhance its core competitiveness and facilitate the transformation of research and development achievements [2] Patent Details - Patent Name: A Taq DNA Polymerase Mutant Mut4 and Its Application [2] - Patent Number: ZL202010980814.1 [2] - Patent Holder: Nanjing Novogene Bioinformatics Technology Co., Ltd. [2] Application and Impact - The patented technology is based on the company's core platform for protein directed evolution and modification, improving enzyme tolerance and amplification performance for high-concentration blood samples [2] - The technology has broad applications in high-throughput sequencing, food safety testing, animal inspection and quarantine, and medical diagnostic testing [2] - The award will not have a significant impact on the company's recent performance [2]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-025 南京诺唯赞生物科技股份有限公司关于 自愿披露获得中国专利优秀奖的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 国家知识产权局于近日发布了《关于第二十五届中国专利奖授奖的决定》（国 知发运字〔2025〕20 号），南京诺唯赞生物科技股份有限公司（以下简称"公 司"）的发明专利"一种 Taq DNA 聚合酶突变体 Mut4 及其应用"荣获第二十五 届中国专利优秀奖，具体情况如下： 中国专利奖是由国家知识产权局与世界知识产权组织共同评选并授予的重要奖 项。该奖项旨在遴选创造质量优、运用效益好、保护能力强、管理水平佳的高价值 专利，以表彰在技术（设计）创新和经济社会发展中做出突出贡献的专利权人及发 明人（设计人），推动科技创新与产业创新深度融合，促进发展新质生产力。 专利名称：一种 Taq DNA 聚合酶突变体 Mut4 及其应用 专 利 号：ZL202010980814.1 专利权人：南京诺唯赞生物科技股份有限公司 该专利系基于公司蛋白质定向改造与进化 ...

Group 1 - The State-owned Assets Supervision and Administration Commission (SASAC) has issued the "Central Enterprise Development Planning Management Measures," establishing a three-level planning system for state-owned enterprises, focusing on optimizing industries and concentrating state capital in key sectors [2] - The Ministry of Industry and Information Technology has called for the promotion of digital, networked, and intelligent upgrades, emphasizing the "Artificial Intelligence + Manufacturing" initiative to enhance key industries [2] - The Shanghai Stock Exchange held a seminar on high-dividend returns, where institutions recognized the strong investment appeal of dividend assets, particularly in banking, energy, and power sectors [2] Group 2 - The first batch of credit bond ETFs for repurchase transactions has been officially launched, with several fund companies approved, which is expected to enhance liquidity and benefit long-term product development [2] - The bond market's "technology board" has seen over 370 billion yuan in issuance, with nearly 79% coming from the interbank market [2] - The China Household Electrical Appliances Association reported that some regions have paused or adjusted the "national subsidy" for old-for-new appliance exchanges due to funding gaps, but further funding is being allocated [2] Group 3 - The company Jinling Sports indicated that the use of its football equipment in some venues of the Scottish Super League has minimal impact on its performance, despite significant stock volatility due to market sentiment [2][7] - The company Vanke A is set to receive a loan of up to 3 billion yuan from Shenzhen Metro Group [7] - The company Stone Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [7]

Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. has signed a strategic cooperation agreement with Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. to establish a joint venture focused on synthetic biology, aiming to enhance technological advancements and project collaboration in the field [1][2]. Agreement Signing Overview - The strategic cooperation agreement does not require approval from the company's board of directors or shareholders [2]. - The agreement does not constitute a related party transaction or a major asset restructuring [2]. - The specific investment scale and construction plan for the joint venture will be determined later, indicating uncertainty [1][2]. Parties Involved - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. is a publicly listed company with a registered capital of 224.87 million yuan and was established in March 2009 [2][3]. - The company has total assets of approximately 507.80 million yuan and a net profit attributable to shareholders of 40.44 million yuan [3]. Joint Venture Details - The joint venture will be co-owned, with Nanjing Novogene holding 49% and Jiangsu Nuotai holding 51% [1][4]. - The project will be implemented in two phases, with the first phase focusing on the renovation and expansion of existing production capacities [4]. - The ultimate goal is to establish an annual production capacity of approximately 10 tons of raw materials and corresponding formulations [4]. Investment and Funding - The specific investment amount will be confirmed by both parties [4]. - Initial funding will come from self-owned funds, with potential project financing for the second phase [4]. Governance Structure - The joint venture will have a board of directors composed of three directors from Jiangsu Nuotai and two from Nanjing Novogene [5]. - The management team will include a general manager nominated by Jiangsu Nuotai and other key positions filled through mutual agreement [5][6]. Operational Management - The joint venture will operate independently, with both parties sharing operational risks and responsibilities [6]. - The agreement includes non-competition clauses and stipulates that both parties will support each other in their respective areas of expertise [6][7]. Impact on Company - This strategic cooperation is expected to enhance the company's core competitiveness in the synthetic biology sector and extend its industrial value chain [7]. - The establishment of the joint venture is subject to regulatory approval and is not expected to significantly impact the company's 2025 performance [7][8].

证券代码：688105 证券简称：诺唯赞 公告编号：2025-024 南京诺唯赞生物科技股份有限公司 关于自愿披露签订战略合作协议 暨拟设立合资公司的公告 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）与江苏诺泰澳 赛诺生物制药股份有限公司（以下简称"诺泰生物"）近日于南京市签署《合成 生物学合作项目战略合作协议》（以下简称"《战略合作协议》"或"协议"）， 以合成生物学技术平台为基础，结合有机合成、化学工艺等交叉技术，共同推进 双方在合成生物学领域的技术进步和项目合作。 公司拟与诺泰生物共同设立一家生物制药公司（以下简称"合资公司" 或"项目公司"，具体名称待定，以市场监督管理机关登记的最终名称为准）， 公司持股比例为 49%，诺泰生物持股比例为 51%，以此为平台开展后续合作与具 体业务工作。合作项目的具体投资规模、建设方案等事项将由双方另行约定并履 行内部审议程序，尚具有不确定性。 本次拟对外投资事项不构成关联交易，也不构成重大资产重组。 风险提 ...

诺唯赞公告，公司与诺泰生物签署《合成生物学合作项目战略合作协议》，并计划共同设立一家生物制 药公司，公司持股比例为49%，诺泰生物持股比例为51%。该合资公司将作为平台，推进双方在合成生 物学领域的技术进步和项目合作。合作项目的具体投资规模、建设方案等事项将由双方另行约定并履行 内部审议程序。合资公司未来业务开展受多方面因素影响，存在不确定性。 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-023 南京诺唯赞生物科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否涉及差异化分红送转：否 ? 每股分配比例 每股现金红利0.15元 ? 相关日期 股权登记日 除权（息）日 现金红利发放日 一、 通过分配方案的股东会届次和日期 三、 相关日期 股权登记日 除权（息）日 现金红利发放日 四、 分配实施办法 无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股 权登记日上海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定 交易的股东派发。已办理指定交易的投资者可于红利发放日在其指定的证券营业 部领取现金红利，未办理指定交易的股东红利暂由中国结算上海分公司保管，待 办理指定交易后再进行派发。 无 （1）对于持有公司无限售条件流通股的自然人股东和证券投资基金，根据《关 于实施上市公司股息红利差别化个人所得税政策有关问题的通知》（财税［2012］ （财税 本次利润分配方案经南京诺唯赞生物科技股份有限公司（以 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-023 南京诺唯赞生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.15元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/4 | 2025/6/5 | 2025/6/5 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经南京诺唯赞生物科技股份有限公司（以下简称"公司"） 2025 年 5 月 19 日的2024年年度股东会审议通过。 二、 分配方案 1. 发放年度：2024年年度 四、 分配实施办法 1. 实施办法 无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股 权登记日上海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定 交易的股东派发。已办理指定交易的投资者可于红利发放日在其指定的证券营业 部领取现金红利，未办理指定交易的股东红利暂由中国结算上海分公司保管，待 ...